In the light of the HER2 and uPAR cooperativity and the common regulatory signaling pathway downstream of HER2 and uPAR in advanced breast carcinoma (Figure 4B), the correlative co-expression pattern of HER2 and uPAR definitely has the potential to act as synergistic targets for therapeutic intervention. Here, ERBB2 is linked to breast carcinoma.